Structure Therapeutics (GPCR) stock and Metsera (MTSR) stock soar as Eli Lilly (LLY) reports promising Phase 3 results for ...

Weight Watchers has outlasted diet fads, rebrands and even logic. But this time, it’s not carbs or keto that brought it down ...

Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial ...

Employer health plans brace for ongoing soaring costs as weight-loss drug utilization rises. What trends are coming down the ...

Scientifically Designed 4-Stage Fat Loss Supplement Offers Safe, Non-Prescription Alternative to GLP-1 Drugs Like ...

Eli Lilly (NYSE:LLY) shares climbed ~14% in the premarket on Thursday after the company said its oral GLP-1 receptor agonist ...

Vivani Medical and Okava expand GLP-1 therapy research to dogs, aiming to advance long-acting treatments for cardiometabolic conditions.

Drugmaker Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce ...

The implications for Eli Lilly and Novo Nordisk seem pretty clear: The immediate removal of a rival for the massive revenues ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...